IP Library Granted Patent US 7,943,168
Granted Patent B2
US 7,943,168 · App. 12/043,063 · Granted May 17, 2011

Nanoparticle delivery systems comprising a hydrophobic core and a lipid/surfactant layer comprising a membrane-lytic peptide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,943,168
App. No.
12/043,063
Granted
May 17, 2011
Kind
B2
Abstract

Compositions which comprise emulsions of nanoparticles for delivery of membrane-integrating peptides are described. The nanoparticles comprise a liquid hydrophobic core coated with a lipid/surfactant layer which contains the membrane-integrating peptides. Methods to use such compositions are also described.

Claims (11)

1. A composition comprising nanoparticles, which nanoparticles comprise a liquid hydrophobic core coating with a lipid/surfactant layer, wherein said lipid/surfactant layer contains at least one membrane-integrating peptide, which is a membrane-lytic peptide.

2. The composition of claim 1 , wherein the hydrophobic core comprises at least one halocarbon compound.

3. The composition of claim 2 , wherein the halocarbon compound is a perfluorocarbon.

4. The composition of claim 1 , wherein the lipid/surfactant layer comprises at least one phospholipid.

5. The compound of claim 1 , wherein the lipid/surfactant layer contains a targeting ligand specific for a target tissue or cell.

6. The composition of claim 5 , wherein the targeting ligand specifically binds an integrin.

7. The composition of claim 1 , wherein the membrane-integrating peptide is cytotoxic.

8. The composition of claim 7 , wherein the membrane-integrating peptide comprises a hydrophobic amino acid sequence of 10-30 amino acids adjacent to a cationic amino acid sequence of 3-6 amino acids.

9. The composition of claim 8 , wherein the membrane-integrating peptide is melittin.

10. The composition of claim 1 , wherein said lipid/surfactant layer further includes a therapeutic or diagnostic agent.

11. The composition of claim 1 , wherein the membrane-integrating peptide is covalently linked to a therapeutic or diagnostic agent.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 3, 2010
From: PROLOG CAPITAL II, L.P.; CHARTER LIFE SCIENCES, L.P.; MEMPHIS BIOMED VENTURES II, L.P.; TRIATHLON MEDICAL VENTURES FUND, L.P.; ADVANTAGE CAPITAL COMMUNITY DEVELOPMENT FUND XV, LLC; ALAFI CAPITAL COMPANY, LLC; APJOHN VENTURES FUND, LP; VECTIS LIFE SCIENCES FUND I, L.P.; WICKLINE, SAMUEL A., M.D.; 1998 CO-INVESTING LLC; C. AGANOSTOPOULOS REVOCABLE TRUST U/A 12/21/1978
To: KEREOS, INC.
Reel/Frame 024320/0741 →
SECURITY AGREEMENT Recorded Jul 17, 2009
From: KEREOS, INC.
To: PROLOG CAPITAL II, L.P.; CHARTER LIFE SCIENCES, L.P.; MEMPHIS BIOMED VENTURES II, L.P.; TRIATHLON MEDICAL VENTURES FUND L.P.; ADVANTAGE CAPITAL COMMUNITY DEVELOPMENT FUND XV, LLC; ALAFI CAPITAL COMPANY, LLC; APJOHN VENTURES FUND, LP; VECTIS LIFE SCIENCES FUND I, L.P.; WICKLINE, SAMUEL A., M.D.; 1998 CO-INVESTING LLC; C. AGANOSTOPOULOS REVOCABLE TRUST U/A 12/21/1978
Reel/Frame 022960/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2008
From: SCHLESINGER, PAUL; SOMAN, NEELESH; LANZA, GREGORY; WICKLINE, SAMUEL A.
To: WASHINGTON UNIVERSITY
Reel/Frame 020821/0229 →